By Mariam Sunny

(Reuters) -The U.S. Food and Drug Administration has approved an injectable version of Eisai and Biogen’s Alzheimer’s disease drug Leqembi, the companies said on Friday, allowing for an easier treatment option following an initial intravenous infusion.

The approval makes Leqembi the first Alzheimer’s treatment that can be administered at home as a weekly under-the-skin injection, reducing the hassle for patients who now need to travel to an infusion center twice a month for the process that takes about an hour.

The potential for at-home administration could also increase the treatment’s availability for other patients, Lynn Kramer, chief clinical officer at Eisai, told Reuters ahead of the decision.

“It actually may open up more infusion chairs for even greater initiati

See Full Page